Supervisor Database Search

Search for supervisors below. You can filter your search using the options and select
multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.

Full NameProfessor Mark Sherlock

Department:Department of Endocrinology

Organisation:Royal College of Surgeons in Ireland

Email Address:Email hidden; Javascript is required.

Research Fields

  • genetics, genomics and molecular biology
  • physiology and non-communicable disease
  • cancer/oncology
  • Other

Other Research Fields:

Endocrinology, Pituitary and Adrenal Disease

Postgrad Medical Specialties

  • Medicine

Medical Subspecialties

  • Cardiology
  • Clinical Trials
  • Endocrinology
  • Pharmacology
  • Physiology

My Work

Our research group is based in Beaumont Hospital/ RCSI, Dublin. Our group focuses on studies related to adrenal disease, pituitary disease and disorders of salt and water balance. Current ongoing work builds on prior published work in areas including:
1. Acromegaly
2. Pituitary tumours and response to therapies
3. Morbidity and mortality outcomes in patients with hypopituitarism
4. Optimisation of glucocorticoid replacement in patients with adrenal insufficiency
5. Hyponatraemia – pathogenesis and treatment

We have a strong track record of publication in the areas above. As a group we collaborate with colleagues in Ireland (Cork and Belfast), UK (Birmingham), Germany and Spain.

Potential Projects

Hyopituitarism is associated with increased mortality and morbidity. At present the underlying mechanisms leading to this adverse phenotype are not clear. Patients with hypopituitarism receive hormone replacement therapy in the form of growth hormone, hydrocortisone, sex steroids and thyroxine. Markers of adequate replacement are crude for a number of these therapies at present and our ongoing work looks at ways to optimise replacement strategies and assess newer markers of replacement adequacy in particular when assessing cortisol replacement.

We aim to prospectively follow patients with pituitary disease to assess the metabolic impact of hypopituitarism. In particular, detailed assessment of cortisol metabolism and markers of cortisol replacement adequacy will be measured as well as the assessment of interventions to optimise glucocorticoid replacement.

It is expected that results of this research will lead to high impact publications, offer novel insights into impact of cortisol deficiency and replacement in hypopituitarism and help identify novel biomarkers to aid with optimisation of therapy. This project would be particularly suited to those interested in Endocrinology and would offer an opportunity to devlelop as a clinician scientist as the research programme will involve both clinical and molecular biology training.

Other potential projects within the unit include:
• Assessment of biomarkers of tumour growth/ aggressiveness and response to treatment in pituitary tumours
• Improving diagnosis and treatment in patients with hyponatraemia
• Assessment of cardiovascular risk and outcomes in patients with acromegaly